Prevor SRL
19.0 FTEThe score of Prevor shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +71 % Equity +128 % Total assets +5 % Headcount (avg FTE) +141 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Prevor's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €3.94m | ||||
| Net result | 288,592 € | ||||
| Equity | €1.35m | ||||
| Cash | 154,182 € | ||||
| EBITDA | 673,493 € | ||||
| Total assets | €3.75m |
Filed annual accounts
- Year ended 31 Jul 2025filed on 28 Apr 2026
- Year ended 31 Jul 2024filed on 19 Nov 2025
- Year ended 31 Jul 2023filed on 20 Jan 2025
- Year ended 31 Jul 2022filed on 10 Feb 2023
- Year ended 31 Jul 2021filed on 17 Mar 2022
Prevor's financial analysis
- Solvency36.1%sector median: 38.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Prevor
Prevor's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0632.637.067
- VAT number
- BE0632637067
- Peppol
- Registered · 0208:0632637067 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 22 Jun 2015
- Registered office
- 4031 Liège
- Size
- Small · 19.0 FTE
- Latest accounts
- 2025 · filed on 28 Apr 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
Prevor (SRL) has been based in Liège since 2015, active in: manufacture of basic pharmaceutical products. For 2025, it reports revenue of €3.94m, a net profit of 288,592 € and equity of €1.35m. With 19.0 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 36.1%, below the median of its sector (38.7%).
Companies similar to Prevor
Companies in the same business, of comparable size and area, outside its group.
- Idevax Manufacture of basic pharmaceutical products Wijnegem · balance sheet €3.95m
- Dr. Naesens en Dr. Kaes Manufacture of basic pharmaceutical products Hasselt · balance sheet €3.39m
- Reprobiol Manufacture of basic pharmaceutical products Ouffet · balance sheet €1.93m
- Spark CRC Manufacture of basic pharmaceutical products Waasmunster · balance sheet €3.11m
- Keminal Manufacture of basic pharmaceutical products Ghent · balance sheet €2.00m
- DR. JAN DE JONGH-Huisarts Manufacture of basic pharmaceutical products Diest · balance sheet €2.13m
- Labo Phytophar Manufacture of condiments and seasonings Oostkamp · balance sheet €10.9m
- Betaplus Pharma Manufacture of basic pharmaceutical products Woluwe-Saint-Lambert · balance sheet €24.9m
Frequently asked questions about Prevor
What is the revenue of Prevor?
According to the 2025 annual accounts filed with the NBB, the revenue of Prevor amounts to 3,935,413 €.
What is the VAT number of Prevor?
In Belgium, the VAT number is the company number prefixed with BE: BE0632637067 for Prevor, if the company is VAT-registered. Its company number (CBE) is 0632.637.067.
Where is the registered office of Prevor?
According to the CBE register, the registered office of Prevor is in 4031 Liège.
What is the equity of Prevor?
At the close of the 2025 financial year, the equity of Prevor amounts to 1,354,170 €, a solvency of 36.1% of total assets.
How many people work at Prevor?
19.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Prevor?
The register lists 2 active mandates at Prevor. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Prevor
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →